Comparing two type of drugs for pain relief in cancer patients

Comparative Evaluation of the Analgesic Efficacy of Transdermal Buprenorphine versus Oral Controlled Release Morphine in Patients with Malignancy. - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/09/094127

Enrollment

Registered

2025-09-02

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

Intervention1: Oral controlled-release morphine tablets: Group A-Oral controlled-release morphine tablets 30mg BD will be given. Pain assessment at 24hr,3 days,7 days,14 days with NRS Control Interven

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged 18 to 65 years with malignancy related severe pain (NRS more than or equal to 7)

Exclusion criteria

Exclusion criteria: 1.Known hypersensitivity to Buprenorphine or Morphine. 2.Severe hepatic or renal impairment 3.Significant respiratory depression or uncontrolled comorbidities. 4.Cognitive impairment preventing self reporting of pain or adverse effects. 5.History suggestive of substance abuse and mental health illness. 6.Current use of strong opioids 7.Ongoing parenteral chemotherapy or radiotherapy 8.Pregnancy and lactation

Design outcomes

Primary

Measure	Time frame
To compare the analgesic effect (using NRS) of transdermal Buprenorphine and Oral controlled release Morphine in patients with malignancy.Timepoint: 24hrs,3 days, 7 days, 14 days after administration of drug.	—

Secondary

Measure	Time frame
To evaluate and compare the patient?s satisfaction and preference using a Likert scale for transdermal Buprenorphine and oral controlled release Morphine in the management of cancer pain.Timepoint: 14 days;To evaluate the quality of life using FACT-G score with the use of transdermal Buprenorphine patch and oral controlled release Morphine in patients with malignancy. Timepoint: 14 days;To evaluate the sleep quality using verbal rating scale with the use of transdermal Buprenorphine patch and oral controlled release Morphine in patients with malignancy Timepoint: 14 days	—

Measure

Time frame

To evaluate and compare the patient?s satisfaction and preference using a Likert scale for transdermal Buprenorphine and oral controlled release Morphine in the management of cancer pain.Timepoint: 14 days;To evaluate the quality of life using FACT-G score with the use of transdermal Buprenorphine patch and oral controlled release Morphine in patients with malignancy. Timepoint: 14 days;To evaluate the sleep quality using verbal rating scale with the use of transdermal Buprenorphine patch and oral controlled release Morphine in patients with malignancy Timepoint: 14 days

—

Countries

India

Contacts

Public ContactDr Dimple pande

VMMC AND SJH

truegemini21@gmail.com9868435534

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026